ArticleFrontiers in pharmacology2025
Tumor-derived extracellular vesicles mediate cell-specific uptake and facilitate enhanced doxorubicin delivery in breast cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy suppresses tumor growth and metastasis, but its efficacy is limited by non-specificity, systemic toxicity, poor accumulation and side effects. Extracellular vesicles (EVs) derived from cells have recently been tested for carrying drugs due to their biocompatibility, stability, and ability to cross biological barriers. We aimed to investigate the potential of drug incorporation to breast cancer (BC) cells-derived EVs and their targeted cell-specific delivery. Methods: EVs were isolated from MDA-MB-231 and MCF7 cells and characterized by nanoparticle tracking analysis and scanning electron microscopy. The cellular uptake of EVs assessed by PKH67 labelling and fluorescent microscopy. Doxorubicin (dox) was incorporated into EVs by sonication, entrapment was confirmed by high-performance liquid chromatography (HPLC). Further, BC cells cytotoxicity, apoptosis, and wound healing was determined for therapeutic efficacy of dox-loaded EVs compared to free dox. Results: EVs had average size of 126.6 ± 58.6 nm (MDA-MB-231) and 163.3 ± 25.7 nm (MCF7), with spherical morphology. EVs exhibited significantly higher autologous uptake compared to allogenic, heterologous or non-cancerous uptake, confirming parent cell-type specificity. Dox entrapment was 22.84% and 29.87%. Furthermore, dox-EVs reduced parent cell viability to 46.1% (MDA-MB-231) and 35.3% (MCF7) compared to free dox treatment (63.4% and 62.1%). Additionally, dox-EVs suppressed wound healing and enhanced apoptosis more effectively than free Dox, while EVs alone promoted cell proliferation. Conclusion: Overall, EVs uptake is cell-specific, and drug incorporation enhanced targeted cell cytotoxicity, highlighting their potential as personalized carriers for precision chemotherapy. However, validation of these results through mechanistic and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.